Study summary

Relacorilant with nab-paclitaxel extended life in platinum-resistant ovarian cancer

ROSELLA trial · Phase 3, randomized · Published June 2025, The Lancet; FDA approved March 2026

What was tested

Relacorilant, a pill that blocks cortisol signals that help tumors resist chemotherapy, plus nab-paclitaxel, against nab-paclitaxel alone for platinum-resistant ovarian cancer.

What they found

Time before growth improved significantly with the combination.
Overall survival was also longer, about 16 vs 12 months in later analyses.

What it means

A new, non-antibody option for platinum-resistant disease (brand name Lifyorli).

Lancet, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.